Gene therapy extended life in mice with inherited heart disease
Among male mice, 69% given gene therapy were alive at 270 days, while controls had a median survival of 197 days.
Our read
Interventions- Studied:
- Experiments in Lmna H222P/H222P mice, 270 days, against vehicle treated male mice
- What changed:
- Among male mice, 69% given gene therapy were alive at 270 days, against median survival of 197 days in controls
- The catch:
- Follow-up ended at 270 days before median survival could be reported for treated mice
- Why it’s aging research:
- It measures how long life or healthy life lasts.
Editor of record: Boris Djordjevic · AgingResearch.News
C57BL/6 mice carrying two copies of the Lmna H222P gene variant received one gene-therapy injection at one month of age in an animal experiment. Lmna encodes lamin A and lamin C, proteins that help maintain the cell nucleus. The therapy combined a component designed to suppress the gene’s activity with a replacement designed to produce both proteins.
Heart pumping function was preserved in treated males at five months and females at 6.5 months compared with littermates given a control injection. Among females, 92% of treated mice remained alive at 300 days, when follow-up ended; controls had a median survival of 235 days. The authors concluded that the approach provided proof of concept for addressing heart and skeletal muscle abnormalities in this mouse model.
Why it matters
Genetic heart and skeletal muscle disease provides a setting to test whether targeting an underlying molecular cause can extend lifespan, rather than managing heart rhythm problems alone.
Caveats
Follow-up ended before median survival could be reported for treated mice. The results came from one engineered mouse model and were reported in a conference abstract.
The paper
Suppression-Replacement Gene Therapy for LMNA -Mediated Cardiomyopathies
Mayo Clinic
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 17398
Comments
Be the first to comment.